Are Pandemic-Era Shopping Shortages Returning? 3 Reasons To Stock Up Now (And 3 Not To)
Learn More:
Find Out:
Earlier this year, a growing number of U.S. consumers said they were stockpiling goods in anticipation of rising prices.
'I'm buying double of whatever — beans, canned goods, flour, you name it,' Thomas Jennings, a shopper in New Jersey, told a Reuters reporter as he prepared for potential price hikes and shortages.
While prices have dominated recent headlines, delays in shipping and customs backlogs are quietly creating stock shortages in key sectors. And, although President Donald Trump's tariffs were recently declared unlawful by the Court of International Trade, they were quickly temporarily reinstated. The Trump administration is also pushing back in an attempt to implement the tariffs, leaving their fate unknown for now.
Are pandemic-era shopping shortages returning? Here are three reasons to stock up now and three reasons not to.
If the tariffs do stick around, here are the reasons you might want to start stocking up.
Read Next:
Shane Lucado, founder and CEO of InPerSuit Inc., a legal technology company, said consumers should watch for signals in logistics contracts and freight indexes.
'When companies start renegotiating delivery terms mid-year, something big is shifting,' Lucado said. 'Freight delays plus tariff spikes mean manufacturers hedge risk by cutting supply. That ripples into job cuts, stock adjustments and vendor shakeups.'
Josh Fischer, vice president of product strategy at Cin7, an inventory management platform, said Chinese imports will be hit the hardest.
'This is going to impact several specific industries, such as electronics, apparel, footwear, auto parts, toys, and sporting goods,' Fischer said. 'The good news is that these aren't the types of products consumers are buying every day. But this will impact seasonal spikes in purchases.'
Baby furniture and European goods are current examples of accessible but vulnerable inventory.
'Purchasing baby furniture is the smartest move right now,' said Johanna Bialkin, CEO of Aldea Home & Baby. 'Gliders, cribs and dressers, especially from Europe, are still in stock and still at a good value right now. We are expecting the tariffs in the EU to drive up demand and pricing.'
Panic won't do you any favors, so make sure you consider the reasons not to stock up before you hit the store.
Acting out of urgency rather than need may leave consumers with items that don't suit their lifestyle or, worse, that they can't return.
'Sometimes people make decisions they regret, like buying a full-size stroller when you actually realize you want something lightweight,' Bialkin said. 'We love the process of education and will continue to leverage our 20 years of expertise to help our consumers buy when it is the right moment.'
Unlike the pandemic, when supply disruptions unfolded gradually and predictably, today's potential trade-related shortages are harder to anticipate.
Factors such as small business closures, volatile pricing and inconsistent trade policies make inventory gaps unpredictable and category-specific. Stockpiling everything 'just in case' could strain household budgets and storage space with little payoff.
'We saw a 44.8% spike in apparel sales during the week of March 31,' said Raj De Datta, CEO and founder of Bloomreach, an AI-driven personalization platform. 'That's consumers trying to get ahead of price hikes due to China-focused tariffs.'
De Datta added, 'When tariffs hit basics, like a $100 shoe line suddenly costing $300, some retailers may pause entire product lines.'
In times of uncertainty, it's natural to consider stocking up on essentials. However, financial experts caution against excessive spending that could jeopardize personal finances and encourage the use of credit cards for everyday purchases.
'Make sure you know where every dollar is going right now, because it's more important than ever to do so,' Thomas Nitzsche, a financial educator at the nonprofit Money Management International (MMI), told NBC10 Boston.
He explained, 'When you see $10 for a dozen eggs, it is really a wake-up call. If it is something you know you'll need, you want to buy now, feel free. But just use caution, because if you finance it, you really got to do the long-term math on that to see, is this really going to make sense? Am I going to end up paying more in interest than I would have saved if I just waited?'
Editor's note on political coverage: GOBankingRates is nonpartisan and strives to cover all aspects of the economy objectively and present balanced reports on politically focused finance stories. You can find more coverage of this topic on GOBankingRates.com.
More From GOBankingRates
Surprising Items People Are Stocking Up On Before Tariff Pains Hit: Is It Smart?
3 Reasons Retired Boomers Shouldn't Give Their Kids a Living Inheritance (And 2 Reasons They Should)
This article originally appeared on GOBankingRates.com: Are Pandemic-Era Shopping Shortages Returning? 3 Reasons To Stock Up Now (And 3 Not To)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Cardinal Health expands urology focus with $1.9bn Solaris Health deal
US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio
Yahoo
11 minutes ago
- Yahoo
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut
President Donald Trump has signaled he may be open to letting Nvidia (NASDAQ:NVDA) ship a toned-down version of its most advanced Blackwell AI chip to China if the company trims its capabilities by 30% to 50%. The comment comes shortly after Trump confirmed an unusual arrangement already in place for Nvidia's less-powerful H20 chip, which allows exports to China in exchange for a 15% revenue share paid directly to the US government. Advanced Micro Devices will follow the same formula for its MI308 chip, according to a person familiar with the matter. Nvidia has not commented on the president's remarks. Warning! GuruFocus has detected 5 Warning Signs with NVDA. The potential deal for Blackwell would mirror Trump's broader push to secure financial returns for the US in exchange for loosening certain export restrictions a strategy that could influence how American companies negotiate market access in China. While Trump didn't outline a specific timeline, he suggested Nvidia CEO Jensen Huang could soon meet with him to discuss a negatively enhanced Blackwell variant. If approved, the move could mark a shift in how high-end US chip technology is selectively offered abroad. Nvidia's Blackwell chips are the backbone of today's most powerful AI systems but remain off-limits to China under current US rules. Both Nvidia and AMD (NASDAQ:AMD) have taken revenue hits as tighter controls limited exports to older models on par with domestic Chinese alternatives products that have struggled to gain traction. Nvidia has already said it is developing another China-specific chip and will seek approval to sell it. The company noted that further cutting back its Hopper-based H20 chip is no longer viable, suggesting a modified Blackwell could be the clearest path to regaining momentum in one of the world's largest AI markets. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data